Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parkinson's disease gene therapy - Oxford BioMedica/Axovant Sciences

Drug Profile

Parkinson's disease gene therapy - Oxford BioMedica/Axovant Sciences

Alternative Names: AXO Lenti PD; OXB-101; OXB-102; ProSavin; Tricistronic lentiviral vector encoding for TH, AADC and CH1 - Oxford BioMedica

Latest Information Update: 31 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Developer Axovant Sciences; Oxford BioMedica
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 25 Oct 2018 Axovant initiates in a phase I/II trial of OXB 102 for Parkinson's disease in United Kingdom (NCT03720418)
  • 06 Jun 2018 Axovant Sciences plans a phase I/II dose-escalation trial of AXO Lenti PD for Parkinson's disease in late 2018
  • 06 Jun 2018 Parkinson's disease gene therapy licensed to Axovant Sciences worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top